Initiation of registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia expected in Q2 2024; Topline data from 1-year open-label extension trial expected Q4 2024; Topline data from registrational Phase 3 RECOVER-2 trial expected Q2 2025; Potential NDA submission for brilaroxazine in schizophrenia targeted for Q3 2025; May initiate Phase 2a studies in bipolar disorder, major depressive disorder, and attention deficit hyperactive disorder in 2024; Investigational new drug application submission for liposomal-gel formulation of brilaroxazine in psoriasis expected in 2025; Pursue partnership opportunities for the development of our pipeline; Evaluate grant and other non-dilutive financing opportunities for our product candidates from Federal and State Healthcare Agencies and Foundations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
- Reviva Pharmaceuticals Holdings, Inc. (RVPH) Q4 Earnings Cheat Sheet
- Reviva to Present at the UBS Virtual CNS Day
- Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
